Pharmacia Switch Focus Impetus For OTC Operations Changes, Relocation
This article was originally published in The Tan Sheet
Executive Summary
Pharmacia is reorganizing its consumer healthcare operations to focus on Rx-to-OTC switches following the firm's merger with Monsanto and its G.D. Searle unit completed in March. The COX-2 inhibitor celecoxib (Celebrex) is a strong switch candidate, Pharmacia said.
You may also be interested in...
Bioenergy Nutrients Respiratory Claims Cited In FDA Courtesy Letter
Three of five products marketed by Amrion's Bioenergy Nutrients division were cited in a May 22 FDA "courtesy" letter for making structure/function claims referring to "respiratory disorders."
Bioenergy Nutrients Respiratory Claims Cited In FDA Courtesy Letter
Three of five products marketed by Amrion's Bioenergy Nutrients division were cited in a May 22 FDA "courtesy" letter for making structure/function claims referring to "respiratory disorders."
Bioenergy Nutrients Respiratory Claims Cited In FDA Courtesy Letter
Three of five products marketed by Amrion's Bioenergy Nutrients division were cited in a May 22 FDA "courtesy" letter for making structure/function claims referring to "respiratory disorders."